Delayed chemotherapy showed no clear difference in overall survival compared with immediate chemotherapy (low certainty).
Chemotherapy + bevacizumab leads to lower overall survival compared with chemotherapy (high certainty).
Chemotherapy probably leads to lower overall survival compared with best supportive care (moderate certainty).
It is very uncertain whether combination chemotherapy changes overall survival (3 years) compared with single‐agent chemotherapy (very low certainty).
It is very uncertain whether FOLFOX + targeted therapy changes overall survival compared with FOLFOX (very low certainty).
FOLFIRI + targeted therapy leads to lower overall survival compared with FOLFIRI (high certainty).
Modern chemotherapy regimens probably leads to lower overall survival compared with 5‐flourouracil (moderate certainty).
Irinotecan + targeted therapy showed no clear difference in overall survival compared with irinotecan (low certainty).
Oral showed no clear difference in overall survival compared with intravenous fluoropyrimidines (high certainty).
Oral showed no clear difference in overall survival compared with intravenous fluoropyrimidines (high certainty).
Irinotecan‐based regimens showed no clear difference in overall survival compared with irinotecan (low certainty).
Irinotecan + oxaliplatin probably leads to lower overall survival compared with irinotecan (moderate certainty).
IRI with fluoropyrimidines showed no clear difference in overall survival (Death) compared with single agent IRI (low certainty).
The review found no eligible studies for this question.